Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib
Bryan Cho Wing Li, Joshua Jing Xi Li, Ka Yu Tse, Haonan Lu, Karen Kar Loen Chan · 2026
Read Targeting KRAS G12C in Rare Mesonephric Carcinoma of the Cervix: A Promising Response to Sotorasib by Bryan Cho Wing Li, Joshua Jing Xi Li, Ka Yu Tse, Haonan Lu, Karen Kar Loen Chan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13155224.txt.
Description
A rare cervical cancer driven by a KRAS mutation gave a fifty-two-year-old woman a long, hard course: surgery, chemoradiation, then spread to lungs, bone, and brain. Bryan Li and co-authors reported in 2026 what happened when she finally received a drug aimed at that exact mutation.
By then she was breathless on oxygen and wheelchair-bound, so doctors started sotorasib at half dose. Within a week her breathing eased and the oxygen came off. She walked unaided and her functional score jumped. The case suggests mutation-matched drugs can rescue even rare cancers late in their course, and argues for genetic testing when standard options run out.
Catalog record
| CREATOR | Bryan Cho Wing Li, Joshua Jing Xi Li, Ka Yu Tse, Haonan Lu, Karen Kar Loen Chan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 9 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |